PRESS RELEASE GE invests in Nanosonics’ novel trophon® EPR technology to help grow sales and marketing in North America Builds on GE Healthcare’s earlier commitment to help establish trophon® EPR as the accepted technology for ultrasound probe reprocessing in North America Sydney, Australia, Wauwatosa, WI and Menlo Park, CA – August 14, 2013 – GE Healthcare and GE Ventures today announced a new sales and marketing investment to accelerate the roll-out of trophon® EPR, a unique system for ultrasound transducer disinfecting developed by Australian-based Nanosonics Limited [ASX: NAN]. This new investment includes the establishment of a dedicated GE Healthcare trophon® EPR sales organization to cover the North American market in collaboration with the current GE Healthcare Ultrasound sales team. In support of the investment made in Nanosonics in June 2012, GE Ventures is making a non-dilutive investment to fund a fully integrated marketing program to accelerate the North American growth strategy.
NAN Price at posting:
78.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)